Terns Pharmaceuticals Inc   (TERN)
Other Ticker:  
Price: $5.2200 $0.77 17.303%
Day's High: $5.26 Week Perf: 35.23 %
Day's Low: $ 4.25 30 Day Perf: -0.57 %
Volume (M): 2,358 52 Wk High: $ 14.04
Volume (M$): $ 12,307 52 Wk Avg: $8.26
Open: $4.46 52 Wk Low: $3.26

 Market Capitalization (Millions $) 373
 Shares Outstanding (Millions) 72
 Employees 51
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -85
 Cash Flow (TTM) (Millions $) -25
 Capital Exp. (TTM) (Millions $) 0

Terns Pharmaceuticals Inc
Terns Pharmaceuticals Inc is a clinical stage biopharmaceutical company that focuses on the discovery and development of innovative small molecule therapies for liver diseases and cancers. The company is based in Foster City, California, and was founded in 201

Terns Pharmaceuticals is led by a seasoned management team with extensive experience in drug discovery, development, and commercialization. The company has established collaborations with leading academic institutions and drug discovery companies to develop novel therapeutics.

The company's lead drug candidate, TERN-101, is a liver-targeted FXR agonist under development for the treatment of non-alcoholic steatohepatitis (NASH), a common liver disease that affects millions of people worldwide. FXR agonists are a class of drugs that activate the farnesoid X receptor, a protein that plays a crucial role in regulating bile acid metabolism and liver function.

TERN-101 has demonstrated promising results in preclinical studies and early clinical trials, showing significant reductions in liver fat and inflammation. The drug has also shown a favorable safety and tolerability profile, with no serious adverse events reported.

In addition to TERN-101, Terns Pharmaceuticals has a pipeline of other small molecule drug candidates under development for the treatment of liver diseases and solid tumors. These drugs target specific pathways and molecular targets involved in the progression and spread of cancer and liver disease.

Terns Pharmaceuticals has received funding from leading venture capital firms, including OrbiMed, Lilly Asia Ventures, and Vivo Capital, among others. The company is also actively seeking partnerships and collaborations to advance its drug development programs and bring novel therapies to patients in need.

   Company Address: 1065 East Hillsdale Blvd Foster City 94404 CA
   Company Phone Number: 525-5535   Stock Exchange / Ticker: NASDAQ TERN
   TERN is expected to report next financial results on March 26, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Conduit Pharmaceuticals Inc

Conduit Pharmaceuticals Inc. Records Operating Shortfall in Q3 2023 but Reveals Promising Financial Indicators

As the earnings cycle for the third quarter of 2023 unfolds, various industries are reporting their financial results. One notable sector is Major Pharmaceutical Preparations, with Conduit Pharmaceuticals Inc being among the corporations announcing its numbers. Despite the absence of realized products and services, the company reported an operating shortfall of $-1.069 million during the July to September 30, 2023 period. However, a closer look at the financials reveals positive indicators, including a significant increase in net profits compared to the previous year. This article aims to analyze and contextualize the financial results of Conduit Pharmaceuticals Inc.
Financial Performance and Stakeholder Expectations:
During the current reporting period, Conduit Pharmaceuticals Inc faced an operating shortfall of $-1.069 million. This unfavorable figure, suggesting a loss for the company, signals the need for additional revenue sources to be explored as soon as possible. However, despite the current financial challenges, stakeholders seem less concerned about the organization's operational excellence and recent developments.

Ayala Pharmaceuticals Inc

ADXS Surpasses Expectations with Strong Third Quarter Results, Drives Optimism in the Pharmaceutical Industry

In the Major Pharmaceutical Preparations industry, where large companies dominate the market, smaller players are making their presence felt with promising results. One such company worth noting is ADXS, which recently announced an operating loss of $-7.131 million for the third quarter of 2023?a significant improvement compared to the same period last year, when the loss was $-7.291 million.
ADXS's positive results come as welcome news, particularly given the lack of easier references in the industry. This performance has generated optimism among market observers, who are now eyeing ADXS as a potential investment opportunity. The company's relentless pursuit of diverse corporate strategies aimed at ensuring new revenue streams has further bolstered this confidence.

Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals Inc Achieves Promising Improvement, Reporting Operating Loss of $-2.543678 Million in Q1 2024

Anebulo Pharmaceuticals Inc, a lesser-known player in the Major Pharmaceutical Preparations sector, recently published their financial numbers for the first quarter of 2024. In a positive surprise for investors and analysts, the company announced that it had realized an operating loss of -$2.543678 million, an improvement from the previous year's operating loss of -$2.612047 million.
What is particularly noteworthy about this improvement is the decrease in diminishing returns, from -$2.612 million in the first quarter of 2023 to -$2.481 million in the same period this year. This suggests that Anebulo Pharmaceuticals Inc is making progress towards becoming an exceptional company in the Healthcare sector.

Qualigen Therapeutics Inc

Lackluster revenue at the Qualigen Therapeutics Inc in the most recent fiscal period

Qualigen Therapeutics Inc stock has seen some fluctuations in recent trading days. However, over the last five trading days, the stock experienced a solid gain of 7.2%. This positive movement comes after a slight decline of -1.91% during the preceding month.
Investors may also note that Qualigen Therapeutics Inc stock is currently trading only 12.3% above its 52-week low. This suggests that the stock has not seen significant upward momentum in recent months.

Onconova Therapeutics Inc

A deficit of $-0.23 per Share at the Onconova Therapeutics Inc amid the fiscal third quarter of 2023

For the fiscal third quarter of 2023 ONTX lost money of $-0.23 per share compare to $-0.26 a year ago and surged deficit from $-0.20 per share from the previous quarter. The revenue remained unaffected by 0 % to $0.06 million from $0.06 million in the same quarter a year ago and sequentially Revenue remained constant from $0.06 million.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com